This indirect, upstream targeting approach differentiates losartan from direct PI3K/Akt inhibitors like alpelisib, which is FDA‐approved for PIK3CA‐mutated breast cancer, and may lead to distinct efficacy and resistance profiles [105]. Here, AKT1 is linked to breast carcinoma.